Sydney, Australia 11 April 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the results of its clinical trial data for its lead product SARTATE™ will be presented by its collaborators at the Peter MacCallum Cancer Centre at the 2016 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The meeting is one of the most prestigious educational and scientific events in the nuclear medicine community and will be held June 11-15 at the Convention Centre in San Diego, California.
SARTATE™ is based on Clarity’s proprietary SAR Technology, which was licensed from the Australian Nuclear Science and Technology Organisation (ANSTO) and the School of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne (UM). The SAR Technology has been validated through the development of the lead product, SARTATE™. Clarity’s strong collaboration with Associate Professor Paul Donnelly at the University of Melbourne enabled the initial manufacture and development of the product that was then translated into the clinic in the recently completed SARTATE™ proof-of-concept clinical trial for neuroendocrine tumours (NETs). Professor Rod Hicks led the trial at the Peter MacCallum Cancer Centre and was accepted to provide an oral presentation on the clinical data for the proof-of-concept study on SARTATE™ in humans as a novel cancer diagnostic for neuroendocrine tumours (NETs) at the 2016 SNMMI Annual Meeting.
Following the first-in-human study, Clarity has already commenced SARTATE™’s development as a cancer therapy for NET patients in a Phase 2a efficacy trial using Copper-64 and Copper-67 pairing. The same product is also being developed for the treatment of neuroblastoma and other children’s cancers. The Company will leverage these studies to demonstrate the commercial potential of SARTATE™ as a product and create new opportunities for the platform SAR Technology to be used for other cancers such as prostate cancer.
Clarity’s CEO Dr Matt Harris commented: “We believe that Clarity is now well positioned to capture multiple opportunities in cancer drug development through validating our technology and capturing the benefits of the Copper-64 and Copper-67 pairing. This theranostic approach is at the forefront of drug development and Clarity has gained strong expertise over the years through translational research and close collaborations with thought leaders in the field.”
Dr Alan Taylor, Executive Chairman at Clarity, added: “Clarity is very lucky to work with the brightest minds in the radiopharmaceutical and oncology fields and to translate their research into the clinic. This current success is the fruits of our long and beneficial relationship with Associate Professor Donnelly at the University of Melbourne and Professor Hicks at the Peter MacCallum Cancer Centre. We have also been very pleased to see continuous support and aspiration for collaboration from the government, academia and industry in an effort to develop internationally competitive treatment solutions and promote Australian science as a whole with the ultimate goal of helping to save people’s lives and reduce post-treatment side effects.”
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
About University of Melbourne
Established in 1853, the University of Melbourne is a public-spirited institution that makes distinctive contributions to society in research, learning and teaching and engagement. It’s consistently ranked among the leading universities in the world, with international rankings of world universities placing it as number 1 in Australia and number 33 in the world.
About Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre is a leading integrated cancer research, treatment and education centre globally. It is one of the few cancer treatment facilities in the world which has a fully integrated clinical and laboratory program situated alongside a hospital. This facilitates the translation of research findings into clinical outcomes within the single site.
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (02) 9209 4037
E: ataylor@claritypharm.com
